Skip to main content
. 2021 Aug 21;12(2):924–938. doi: 10.1016/j.apsb.2021.08.018

Figure 3.

Figure 3

Both treatment with LPs-R848 and modification of LPs with MM could enhance the in vivo ingestion of nanoparticles by neutrophils, which in turn facilitated nanoparticle accumulation at tumor sites. (A–F) LPs-DiD and MM-LPs-DiD were i.v. injected into tumor-bearing mice with or without LPs-R848 pretreatment. At different time intervals post nanoparticle injection, the tumors and blood were harvested to analyze the DiD+ neutrophil percentage using flow cytometry. After injection of LPs-DiD, the change in DiD+ neutrophil percentage in the blood of (A) the control group or (B) LPs-R848-pretreated group was determined (n=5). Corresponding histograms of (C) the blood sample and (D) tumor tissue (n=5). (E) Quantitative figure comparing the DiD+ neutrophil percentage between the LPs-DiD group and MM-LPs-DiD group at 4 h after injection without LPs-R848 pretreatment (n=5). (F) Quantitative figure comparing the DiD+ neutrophil percentage between the LPs-DiD group and the MM-LPs-DiD group at 1 h after injection with LPs-R848 pretreatment (n=5). (G) In vivo imaging of mice and (H) ex vivo imaging of organs at different time points after injection of LPs-DiD or MM-LPs-DiD with or without LPs-R848 pretreatment (n = 3). Data are shown as the mean±SD and analyzed by unpaired two-tailed Student's t-test. ∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001, ∗∗∗∗P<0.0001. n.s., not significant.